Simpson Interventions Welcomes New CEO

Simpson Interventions Inc. has appointed Joseph Knight, Ph.D., as CEO, succeeding Founder and former chief executive John B. Simpson, Ph.D., M.D.

Simpson will remain board chairman and become the company’s chief medical officer. He’s led Simpson Interventions since its 2019 founding. “I’ve always believed my strength lies in taking a company from the ‘device drawing on a napkin’ phase to the ‘First in Human’ phase,” Dr. Simpson said. “Now that we have reached this milestone, it is the perfect time to bring in a leader with the operational expertise to guide us through the next stages of growth. Dr. Knight is well-suited for this role, and I am thrilled to support him as chief medical officer while we continue to revolutionize interventional cardiology together. His story is profoundly inspiring, and I am confident he will lead Simpson Interventions to new heights.”

Dr. Knight most recently worked as president and CEO of InnAVasc Medical until the company was acquired by W. L. Gore & Associates. Additionally, Dr. Knight has been part of the intellectual property development, business, and strategic planning for multiple early-stage ventures—including iRhythm Technologies, Lacuna Medial, Higgs Boson Health, and Medici Medical Technologies. Dr. Knight also spent five years at Medtronic in various marketing, business development, and strategy roles. Dr. Knight’s extensive academic credentials include a Ph.D. from the Swiss Federal Institute of Technology (ETH Zurich), an MBA in entrepreneurship and marketing form Duke University’s Fuqua School of Business, bachelor and masters degrees in engineering from the University of South Florida and as a Fellow in Stanford University’s Biodesign Innovation Program.

“I’m thrilled to take the leadership mantle from Dr. Simpson, who has been a luminary in the field of cardiovascular medicine for generations,” Dr. Knight stated. “Not only has Dr. Simpson grown Simpson Interventions into a company at the forefront of breakthroughs in interventional cardiology (IC), but he’s also had the foresight to tackle the complex problems that have plagued the interventional cardiology community for decades. I’m honored to be able to follow in his footsteps and lead this great company forward.”

Simpson Interventions is a medical technology company committed to addressing unmet clinical needs in cardiovascular diseases through technological innovations in visual-guidance, enhanced intelligence, and electromechanical automation for minimally invasive percutaneous intervention.